Barclays Downgrades Xylem to Equal-Weight, Cuts Target to $104; UBS Trims to $99
UBS kept its neutral rating and lowered its price target to $99 from $112 in the same session.
Key points
- Barclays downgraded Xylem to equal-weight from overweight, target cut to $104 from $139
- UBS kept neutral rating, target cut to $99 from $112
- Stock rose 2.9% Thursday to close at $90.76; S&P 500 ETF fell 0.4%
- Median target across 14 covering firms was $135 before the actions
Analyst moves
Barclays downgraded Xylem (NYSE: XYL) to equal-weight from overweight on Thursday, Oct. 29, and cut its price target to $104 from $139. The action came before the open.
UBS maintained its neutral rating and cut its price target to $99 from $112 during the session. Two firms acted on the stock that day, and neither raised a target.
Price and coverage
Xylem closed at $88.23 on Wednesday, Oct. 28, the last close before the actions, and the stock had fallen 12.9% over the 20 sessions to that close. On Thursday the stock rose 2.9% to close at $90.76, while the S&P 500 ETF fell 0.4%.
Of the 14 firms that rated Xylem in the past year, 10 held positive ratings, three held neutral ratings and one held a negative rating before Thursday. The median target among those firms was $135. The two new targets, $104 and $99, both sit below that median.
Before the actions, Xylem's market capitalization was about $20.23 billion. Revenue for the last fiscal year, ended Dec. 31, 2025, was $9.04 billion, up 6% from a year earlier.
Written with AI from analyst rating changes, SEC filings and market data, and checked against those sources before publishing. Our editorial standards.
More on Xylem
XYL page →Filings, figures and price history are on the Xylem page.